Literature DB >> 33159640

Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients.

Bingwen Eugene Fan1,2,3,4, Thirugnanam Umapathi5,6,7, Karen Chua5,6,8, Yew Woon Chia5,6,9, Shiun Woei Wong5,6,9, Glenn Wei Leong Tan5,6,10, Sadhana Chandrasekar5,6,10, Ying Hui Lum8, Shawn Vasoo5,6,11,12, Rinkoo Dalan5,6,13.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 33159640      PMCID: PMC7648538          DOI: 10.1007/s11239-020-02332-z

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


× No keyword cloud information.
We read with interest the editorial “Anticipating the long-term cardiovascular effects of COVID-19 [1]” which featured COVID-19 end-organ thrombotic complications. COVID-19 associated hypercoagulability [2] and increased thromboembolism in COVID-19 has been well described [3]. While the editorial raised the key question about “potential long-term cardiovascular effects (of COVID-19)”, little is known about the post COVID-19 vascular complications. In response, we would like to highlight a series of catastrophic arterial events observed in post COVID-19 patients (Table 1), echoing the Editor’s concerns of post-infectious vasculopathy.
Table 1

Four cases of post COVID-19 acute arterial thromboses

NoAgeEthnic groupSexPresentationArterial events and co-morbiditiesImagingSARS-CoV total antibodySARS-CoV PCRDate of arterial eventDays from positive serology to thrombosisTreatmentInitial haemostatic assessmentRepeat haemostatic assessmentCurrent status
138IndianM

Fall with Acute right sided weakness

Global aphasia NIHSS: 23

Acute left MCA infarct

No comorbidities

MRI brain

Diffuse loss of grey-white differentiation and restricted diffusion involving the left fronto-parieto-temporal lobes and left basal ganglia

Positive × 1

27 May

Not tested7 July41 days

1.IV rtPA

2.Endovascular therapy

3. Aspirin

PT 13.5

APTT 26.4

D-dimer 3.20

Fibrinogen 2.7

vWF 260%

Factor VIII NA

Platelets 227

22 July > 3 Aug > 7 Oct

PT 14.3 > 13.5 > 13.3

APTT 28.8 > 31.1 > 27.1

D-dimer 3.39 > 1.22 > 0.46

Fibrinogen 7.5 > 5.6 > 3.3

vWF 272% > 240% > 186%

Factor VIII 208% (7 Oct)

Platelets 583 > 369 > 256

71 days in Rehabilitation
239IndianM

Acute right sided weakness

Global aphasia

NIHSS: 25

Left MCA and PCA infarct

Pulmonary Embolism

Infrarenal aortic thrombus

Newly diagnosed DM

MRI brain

Large area of restricted diffusion is noted in the left fronto-parieto-temporal lobes, the left occipital and posterior medial temporal lobes

CT pulmonary angiogram

Thrombi seen in the right lower lobe, left upper lobe, left lower lobar, segmental and segmental branches. The main pulmonary arteries have no filling defects seen

CT abdomen/pelvis

Eccentric mural thrombus in the infrarenal aorta

Positive × 2

21 May

14 Aug

Negative × 2

20 Aug

21 Aug

5 Aug76 days

1.Thrombectomy

2.Craniectomy

3.Low molecular weight heparin with bridging to warfarin

PT 13.7

APTT 26.6

D-dimer 3.55

Fibrinogen 5.8

vWF 226%

Factor VIII 238%

Platelets 301

30 Sept

PT 30.9

APTT 38.4

Fibrinogen 4.7

vWF 153%

Factor VIII 217%

Platelets 256

30 days in Rehabilitation
349IndianMLeft acute painful lower limb

Left acute ischaemic limb

Infrarenal aortic thrombus

No comorbidities

CT angiography

Occlusion of the left popliteal artery extending to tibioperoneal trunk and into the origins of the ATA, PTA and peroneal arteries. Aetiology is likely an embolus from the distal aorta/left common iliac artery

Positive × 1

3 June

Negative × 3

12 May

21 May

2 Sept

2 Sept91 days

1.Thrombectomy

2.IV Heparin followed by Rivaroxaban

PT 13.1

APTT 26.7

D-dimer 0.42

Fibrinogen NA

Factor VIII 216%

vWF 161%

Platelets 256

Not assessed yet as thrombotic event was recentDischarged Home Well
438IndianMChest pain and sudden collapse

ST-Elevation myocardial infarction

No comorbidities

Coronary angiogram

1. Dominance—Right-dominant

2. LM—Free of significant disease

3. LAD—Ostial LAD occluded

4. LCx—Normal

5. Ramus intermedius ( RI)—Normal

6. RCA – Normal

Positive × 1

9 July

Negative × 1

29 May

Negative × 4

24 June

27 Sept

28 Sept

3 Oct

27 Sept80 days

1.PCI with drug eluting stent to LAD

2. Intraaortic balloon pump

3. Heparin

4. Aspirin

5. Ticagrelor

PT 15.7

APTT 31.8

D-dimer 4.11

Fibrinogen 5.2

vWF 374%

Platelets 156

Not assessed yet as thrombotic event was recentAdmitted to cardiac intensive care unit

NIHSS National Institutes of Health Stroke Scale, MCA middle cerebral artery, PCA posterior cerebral artery, MRI magnetic resonance imaging, IV rTPA intravenous recombinant tissue plasminogen activator, CT computer tomography, DM diabetes mellitus, LM left main, LAD left anterior descending artery, LCx left circumflex artery, RCA right coronary artery, PCI percutaneous coronary intervention, NA not available

Prothrombin Time (PT): 11.7–14.0 s. Activated partial thromboplastin time (aPTT): 27.0–37.0 s. Fibrinogen: 1.8–4.5 g/L. D-Dimer: < 0.5 μg/ml. Platelets: 150–360 × 109/L. Factor VIII: 60–150%. Von Willebrand Factor (vWF): 56–160%

Four cases of post COVID-19 acute arterial thromboses Fall with Acute right sided weakness Global aphasia NIHSS: 23 Acute left MCA infarct No comorbidities MRI brain Diffuse loss of grey-white differentiation and restricted diffusion involving the left fronto-parieto-temporal lobes and left basal ganglia Positive × 1 27 May 1.IV rtPA 2.Endovascular therapy 3. Aspirin PT 13.5 APTT 26.4 D-dimer 3.20 Fibrinogen 2.7 vWF 260% Factor VIII NA Platelets 227 22 July > 3 Aug > 7 Oct PT 14.3 > 13.5 > 13.3 APTT 28.8 > 31.1 > 27.1 D-dimer 3.39 > 1.22 > 0.46 Fibrinogen 7.5 > 5.6 > 3.3 vWF 272% > 240% > 186% Factor VIII 208% (7 Oct) Platelets 583 > 369 > 256 Acute right sided weakness Global aphasia NIHSS: 25 Left MCA and PCA infarct Pulmonary Embolism Infrarenal aortic thrombus Newly diagnosed DM MRI brain Large area of restricted diffusion is noted in the left fronto-parieto-temporal lobes, the left occipital and posterior medial temporal lobes CT pulmonary angiogram Thrombi seen in the right lower lobe, left upper lobe, left lower lobar, segmental and segmental branches. The main pulmonary arteries have no filling defects seen CT abdomen/pelvis Eccentric mural thrombus in the infrarenal aorta Positive × 2 21 May 14 Aug Negative × 2 20 Aug 21 Aug 1.Thrombectomy 2.Craniectomy 3.Low molecular weight heparin with bridging to warfarin PT 13.7 APTT 26.6 D-dimer 3.55 Fibrinogen 5.8 vWF 226% Factor VIII 238% Platelets 301 30 Sept PT 30.9 APTT 38.4 Fibrinogen 4.7 vWF 153% Factor VIII 217% Platelets 256 Left acute ischaemic limb Infrarenal aortic thrombus No comorbidities CT angiography Occlusion of the left popliteal artery extending to tibioperoneal trunk and into the origins of the ATA, PTA and peroneal arteries. Aetiology is likely an embolus from the distal aorta/left common iliac artery Positive × 1 3 June Negative × 3 12 May 21 May 2 Sept 1.Thrombectomy 2.IV Heparin followed by Rivaroxaban PT 13.1 APTT 26.7 D-dimer 0.42 Fibrinogen NA Factor VIII 216% vWF 161% Platelets 256 ST-Elevation myocardial infarction No comorbidities Coronary angiogram 1. Dominance—Right-dominant 2. LM—Free of significant disease 3. LAD—Ostial LAD occluded 4. LCx—Normal 5. Ramus intermedius ( RI)—Normal 6. RCA – Normal Positive × 1 9 July Negative × 1 29 May Negative × 4 24 June 27 Sept 28 Sept 3 Oct 1.PCI with drug eluting stent to LAD 2. Intraaortic balloon pump 3. Heparin 4. Aspirin 5. Ticagrelor PT 15.7 APTT 31.8 D-dimer 4.11 Fibrinogen 5.2 vWF 374% Platelets 156 NIHSS National Institutes of Health Stroke Scale, MCA middle cerebral artery, PCA posterior cerebral artery, MRI magnetic resonance imaging, IV rTPA intravenous recombinant tissue plasminogen activator, CT computer tomography, DM diabetes mellitus, LM left main, LAD left anterior descending artery, LCx left circumflex artery, RCA right coronary artery, PCI percutaneous coronary intervention, NA not available Prothrombin Time (PT): 11.7–14.0 s. Activated partial thromboplastin time (aPTT): 27.0–37.0 s. Fibrinogen: 1.8–4.5 g/L. D-Dimer: < 0.5 μg/ml. Platelets: 150–360 × 109/L. Factor VIII: 60–150%. Von Willebrand Factor (vWF): 56–160% During the months of April 2020 to July 2020, Singapore experienced a surge in COVID-19 cases amongst our migrant workers. Subsequently, in July 2020 to September 2020, 4 young healthy migrant workers presented with catastrophic, large arterial thromboses. They were detected to have COVID-19 during routine screening of affected migrant workers’ dormitories. They had raised Immunoglobulin G for SARS-CoV-2 (Roche Elecsys Anti-SARS-CoV-2) indicative of COVID-19 seroconversion. They were asymptomatic and did not meet criteria necessitating hospitalization nor thromboprophylaxis and were quarantined at isolation facilities. Subsequently, they presented with a sentinel thrombotic event at a median of 78 days from seroconversion. Their median age was 38.5 years, and they were of South Asian ethnicity. Cardiovascular risk factors screening showed that one had recently diagnosed diabetes mellitus with a HbA1c of 6.7% whilst the others did not have any risk factors. Two patients suffered from severe large vessel ischaemic strokes (Fig. 1a–d), one had an acute ischaemic limb (Fig. 2a) due to emboli from an aortic thrombosis (Fig. 2b), and one had anterolateral ST-Elevation Myocardial Infarction (Fig. 3a–c). No features of overt arteriosclerotic disease were found during neuroimaging, CT angiography and coronary angiography. Thrombophilia screen and stroke evaluation inclusive of carotid imaging, echocardiography, 24-h holter monitoring were normal.
Fig. 1

a-d Acute magnetic resonance brain images of the 2 patients with large vessel ischaemic stroke. They show large areas of restricted diffusion in left middle cerebral, and middle cerebral, posterior cerebral artery territories, respectively. Adjoining intracranial magnetic resonance angiograms show loss of normal flow void in the left internal carotid and middle cerebral arteries in the first patient (a, b), and M1 segment of left middle cerebral artery in the second patient (c, d)

Fig. 2

a An eccentric thrombus (white arrow) is present in the distal aorta just before its bifurcation. b An abrupt cut off of the left popliteal artery (blue arrow)

Fig. 3

a Coronary angiogram showed complete occlusion of ostial left anterior descending artery (LAD). Left circumflex artery and ramus intermedius branch are normal. b Restoration of flow in the LAD after implantation of drug eluting stent. c Intravascular ultrasound (virtual histology) showed predominantly fibrotic plaque with minimal necrotic core in the ostial LAD

a-d Acute magnetic resonance brain images of the 2 patients with large vessel ischaemic stroke. They show large areas of restricted diffusion in left middle cerebral, and middle cerebral, posterior cerebral artery territories, respectively. Adjoining intracranial magnetic resonance angiograms show loss of normal flow void in the left internal carotid and middle cerebral arteries in the first patient (a, b), and M1 segment of left middle cerebral artery in the second patient (c, d) a An eccentric thrombus (white arrow) is present in the distal aorta just before its bifurcation. b An abrupt cut off of the left popliteal artery (blue arrow) a Coronary angiogram showed complete occlusion of ostial left anterior descending artery (LAD). Left circumflex artery and ramus intermedius branch are normal. b Restoration of flow in the LAD after implantation of drug eluting stent. c Intravascular ultrasound (virtual histology) showed predominantly fibrotic plaque with minimal necrotic core in the ostial LAD The remarkable features of these cases include young age without preexisting cardiovascular risk factors, asymptomatic SARS-CoV-2 infection and the long latency between initial positive serology and their catastrophic vascular event. Firstly, two patients had an unusual site of thrombosis, with mobile aortic thromboses discovered on CT imaging. Aortic thrombosis is rare in young patients without a significant thromboembolic risk factors or pre-existing arteriosclerosis. The SARS-CoV-2 virus is known to cause endothelial damage during acute infection [4, 5] and cases of COVID-19 associated acute ischaemic limb secondary to embolism from aortic thrombosis have been described [6, 7]. However, less is known about persistence of endotheliitis in the convalescent phase of illness. We postulate that post SARS-CoV-2 infection, a state of endothelial activation with downstream signaling pathways of low-grade inflammation and thrombosis may persist [8]. Similar mural thrombosis has been described in patients on chemotherapy and has been attributed to trauma to vascular endothelium and a hypercoagulable state [9]. However, our patients did not consume any medications and did not have any endovascular lines. The aortic thrombosis in COVID-19 could be a consequence of persistent endothelial dysfunction due to viral inclusion bodies at specific sites (this has been reported in Chilblains (‘COVID toes’) in children and young adults [10]) Secondly, haemostatic assessment of the 4 patients at time of acute thrombosis highly suggested a hypercoagulable state, with a markedly raised Factor VIII, elevated von Willebrand factor antigen, increased D-dimer levels and hyperfibrinogenaemia. Both endothelial dysfunction and hypercoagulability are 2 key factors in Virchow’s triad for thrombosis. The post-thrombosis evaluation of the haemostatic profile in 2 of our patients with ischaemic stroke at a 2 to 3-month window from onset of acute stroke revealed declining but persistently raised von Willebrand factor antigen, Factor VIII, and fibrinogen levels. A persistently raised von Willebrand factor may reflect chronic endothelial activation and dysfunction [11], as well as ongoing platelet hyperactivation [12]. Thirdly, for the young patient with cardiac arrest and acute myocardial infarction, COVID-19 may have induced an ‘accelerated atherosclerosis’ and precipitated a coronary event during his convalescence. There was complete occlusion of left anterior descending (LAD) artery (Fig. 3a). This is suggested by findings from Intravascular ultrasound (Volcano Eagle Eye catheter) which was used to interrogate the LAD artery. Small amount of clot was retrieved using thrombectomy device. It showed a focal heavily fibrous plaque burden of 59% and minimal lumen diameter of 2.1 mm in the ostial LAD (Fig. 3c), with a plaque burden of more than 70% and minimal lumen area of less than 4mm2 being independent predictors of major adverse cardiovascular events [13]. This is unusual as fibrotic lesions are usually deprived from lipid and inflammatory cells and hence less likely to rupture and generate thrombosis [14]. COVID-19 is known to cause cardiac complications with a case series from China reporting a high percentage (19.7%) of COVID 19 patients having evidence of myocardial injury with 51% in-hospital mortality compared with 4.5% without raised troponin [15]. Potential mechanisms that explain cardiac injury during acute infection include (i) imbalance in myocardial demand and supply due to tachycardia and hypotension from type 2 myocardial infarction; (ii) acute atherothrombosis in a virally induced thrombotic and inflammatory milieu; (iii) microvascular dysfunction from microthrombi or endothelial injury; (iv) stress-related cardiomyopathy (Takotsubo) and (v) direct cardiomyocyte toxicity and myocarditis, of which artherothrombosis as well as direct cardiomyocyte toxicity may cause sustained long-term damage to the coronary vessels and the myocardium, with 10 patients in Germany critically ill with COVID-19 demonstrating low to no detectable virus in myocardial tissues despite multiple microemboli in the heart [16]. These observations suggest that the SARS-CoV-2 virus poses significant and chronic immuno-thrombogenicity which may cumulate eventually in a major thrombotic event. Although small, our case series suggests that catastrophic vascular events can occur unexpectedly in fit patients with mild or asymptomatic COVID-19 infection and may unpredictably happen many weeks later. The COVID-19 pandemic has a prolonged and serious impact on the cardiovascular health of patients. Hence for convalescent patients, regardless of the severity of infection and the absence of co-morbidities, clinicians should remain vigilant for post-infective thrombotic sequelae as well as consider screening for and closely managing cardiovascular risk factors. Multi-disciplinary collaboration into the epidemiology, pathogenesis and treatment of COVID-19 associated thrombosis and in evaluating the utility of extended thromboprophylaxis for COVID-19 patients should be strongly considered.
  16 in total

1.  Multimodality Intravascular Imaging to Evaluate Sex Differences in Plaque Morphology in Stable CAD.

Authors:  Aditya S Bharadwaj; Yuliya Vengrenyuk; Takahiro Yoshimura; Usman Baber; Choudhury Hasan; Jagat Narula; Samin K Sharma; Annapoorna S Kini
Journal:  JACC Cardiovasc Imaging       Date:  2016-04

2.  Acute aortic thrombosis presenting as acute limb ischemia in two young, non-atherosclerotic patients.

Authors:  S S N Goh; E M Yong; Q T Hong; J Z Lo; S Chandrasekar; J J Ng; Y W Chia; E B Fan; L M Ling; P M P Wong; N K X Wee; S Punamiya; H H L Quek; U Pua; G W L Tan
Journal:  Br J Surg       Date:  2020-08-10       Impact factor: 6.939

3.  The implications of COVID-19 infection on the endothelium: A metabolic vascular perspective.

Authors:  Rinkoo Dalan; Bernhard O Boehm
Journal:  Diabetes Metab Res Rev       Date:  2020-09-09       Impact factor: 4.876

4.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.

Authors:  Shaobo Shi; Mu Qin; Bo Shen; Yuli Cai; Tao Liu; Fan Yang; Wei Gong; Xu Liu; Jinjun Liang; Qinyan Zhao; He Huang; Bo Yang; Congxin Huang
Journal:  JAMA Cardiol       Date:  2020-07-01       Impact factor: 14.676

Review 5.  COVID-19-associated vasculitis and vasculopathy.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2020-10       Impact factor: 2.300

6.  Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.

Authors:  George Goshua; Alexander B Pine; Matthew L Meizlish; C-Hong Chang; Hanming Zhang; Parveen Bahel; Audrey Baluha; Noffar Bar; Robert D Bona; Adrienne J Burns; Charles S Dela Cruz; Anne Dumont; Stephanie Halene; John Hwa; Jonathan Koff; Hope Menninger; Natalia Neparidze; Christina Price; Jonathan M Siner; Christopher Tormey; Henry M Rinder; Hyung J Chun; Alfred I Lee
Journal:  Lancet Haematol       Date:  2020-06-30       Impact factor: 18.959

7.  Microthrombi and ST-Segment-Elevation Myocardial Infarction in COVID-19.

Authors:  Giulio Guagliumi; Aurelio Sonzogni; Irene Pescetelli; Dario Pellegrini; Aloke V Finn
Journal:  Circulation       Date:  2020-07-17       Impact factor: 29.690

8.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19.

Authors:  F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D A M P J Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman
Journal:  Thromb Res       Date:  2020-04-10       Impact factor: 3.944

9.  Platelets Can Associate with SARS-Cov-2 RNA and Are Hyperactivated in COVID-19.

Authors:  Younes Zaid; Florian Puhm; Isabelle Allaeys; Abdallah Naya; Mounia Oudghiri; Loubna Khalki; Youness Limami; Nabil Zaid; Khalid Sadki; Rafiqua Ben El Haj; Wissal Mahir; Lamiae Belayachi; Bouchra Belefquih; Amina Benouda; Amine Cheikh; Marc-André Langlois; Yahia Cherrah; Louis Flamand; Fadila Guessous; Eric Boilard
Journal:  Circ Res       Date:  2020-09-17       Impact factor: 17.367

10.  COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis.

Authors:  Ponnudurai Kuperan; Yew Woon Chia; Bingwen Eugene Fan; Jensen Ng; Stephrene Seok Wei Chan; Dheepa Christopher; Allison Ching Yee Tso; Li Min Ling; Barnaby Edward Young; Lester Jun Long Wong; Christina Lai Lin Sum; Hwee Tat Tan; Mui Kia Ang; Gek Hsiang Lim; Kiat Hoe Ong
Journal:  J Thromb Thrombolysis       Date:  2020-10-24       Impact factor: 2.300

View more
  19 in total

Review 1.  Significance of NETs Formation in COVID-19.

Authors:  Karolina Janiuk; Ewa Jabłońska; Marzena Garley
Journal:  Cells       Date:  2021-01-14       Impact factor: 6.600

Review 2.  Fundamentals in Covid-19-Associated Thrombosis: Molecular and Cellular Aspects.

Authors:  Daniella M Mizurini; Eugenio D Hottz; Patrícia T Bozza; Robson Q Monteiro
Journal:  Front Cardiovasc Med       Date:  2021-12-17

Review 3.  Post-Acute COVID-19 Syndrome for Anesthesiologists: A Narrative Review and a Pragmatic Approach to Clinical Care.

Authors:  Rafal Kopanczyk; Nicolas Kumar; Thomas Papadimos
Journal:  J Cardiothorac Vasc Anesth       Date:  2021-10-03       Impact factor: 2.894

Review 4.  High levels of Von Willebrand factor markers in COVID-19: a systematic review and meta-analysis.

Authors:  Mehrdad Rostami; Hassan Mansouritorghabeh; Mohammad Parsa-Kondelaji
Journal:  Clin Exp Med       Date:  2021-11-06       Impact factor: 5.057

5.  Case Report: Asymptomatic COVID-19 patient with a subtle hypercoagulable state and fluctuating D-dimer level.

Authors:  Jefferson Caesario; Decsa M Hertanto; Kukuh D Hernugrahanto; Dwikora N Utomo; Nicolaas C Budhiparama; Djoko Santoso; Pancras C W Hogendoorn
Journal:  F1000Res       Date:  2021-11-03

6.  Towards better understanding of the heparin role in NETosis: feasibility of using native mass spectrometry to monitor interactions of neutrophil elastase with heparin oligomers.

Authors:  Chendi Niu; Yi Du; Igor A Kaltashov
Journal:  Int J Mass Spectrom       Date:  2021-02-14       Impact factor: 1.986

7.  Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review.

Authors:  Mohammad Said Ramadan; Lorenzo Bertolino; Rosa Zampino; Emanuele Durante-Mangoni
Journal:  Clin Microbiol Infect       Date:  2021-06-23       Impact factor: 13.310

Review 8.  Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review.

Authors:  Michael Joseph Cryer; Serdar Farhan; Christoph C Kaufmann; Bernhard Jäger; Aakash Garg; Prakash Krishnan; Roxana Mehran; Kurt Huber
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

9.  Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study-Reply to comment from Muzaffar et al.

Authors:  Bingwen Eugene Fan; Yew Woon Chia; Gek Hsiang Lim; Chwee Fang Bok; Shiun Woei Wong
Journal:  J Thromb Thrombolysis       Date:  2022-02-03       Impact factor: 5.221

Review 10.  Post-COVID syndrome: pulmonary complications

Authors:  Dorina Esendağli; Aydin Yilmaz; Şule Akçay; Tevfik Özlü
Journal:  Turk J Med Sci       Date:  2021-12-17       Impact factor: 0.973

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.